InvestorsHub Logo

DewDiligence

03/26/20 5:57 PM

#229879 RE: DewDiligence #229875

Addendum—ENTA’s COVID-19 PR is silent about expected Mavyret royalties from ABBV. ENTA is not in a position to comment on this until ABBV does.

I expect some degradation in Mavyret royalties from the COVID-19 outbreak, as there will certainly be fewer patients starting HCV drugs during the next several months. However, this patient-start shortfall ought to be temporary insofar as people who defer HCV treatment are still going to need it, unless they die in the interim.